Arrivent Biopharma Inc (AVBP)

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for patients with cancers that still have significant unmet medical needs. The company’s lead program is firmonertinib, a tyrosine kinase inhibitor being studied in multiple clinical trials across several epidermal growth factor receptor mutant (EGFRm) forms of non-small cell lung cancer, including a Phase 3 study in advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. ArriVent is also advancing ARR-217, an antibody-drug conjugate for gastrointestinal cancers, along with ARR-002, ARR-421, and ARR-173 for solid tumors. The company has collaboration agreements with Aarvik Therapeutics, Shanghai Allist Pharmaceuticals, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, and Lepu Biopharma. Incorporated in 2021, ArriVent BioPharma is based in Newtown Square, Pennsylvania, and its common stock trades on NASDAQ under the symbol AVBP.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.